Genmab AS (GMAB)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $31.67B
Last updated: Nov 17, 2026 at 11:06 AM ET
Genmab AS (GMAB) P/E Ratio & Valuation Multiples
Genmab AS (GMAB) trades at 35.8x trailing earnings and 19.2x sales. Its P/S of 19.2x is above its 5-year median of 12.3x. Its forward P/E is 22.2x. The median P/E across 5 similar companies is 19.3x.
Current Multiples
Its forward P/E is below its trailing P/E, which implies earnings per share about 61.3% higher over the next year. Its free cash flow yield is 1.8%.
| Multiple | Value |
|---|---|
| P/E (trailing) | 35.8x |
| Forward P/E | 22.2x |
| Price to sales | 19.2x |
| Price to book | 5.1x |
| EV/EBITDA | 58.3x |
| Price to FCF | 57.0x |
| EV/FCF | 62.6x |
| PEG | 4.6 |
| FCF yield | 1.8% |
Historical Medians
Against its 10-year medians, its P/B is 33.8% below 7.7x.
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/S | 19.2x | 12.3x | N/A |
| P/B | 5.1x | 6.6x | 7.7x |
Valuation History
Over the 7 of the 10 year ends shown that have a P/S, its P/S ranged from 7.0x in 2024 to 40.3x in 2025. 2025 was the highest of those years.
| Year end | Price | P/S | P/B |
|---|---|---|---|
| 2025 | $30.80 | 40.3x | 22.6x |
| 2024 | $20.87 | 7.0x | 2.6x |
| 2023 | $31.84 | 8.8x | 4.5x |
| 2022 | $42.38 | 13.7x | 7.1x |
| 2021 | $39.56 | 19.7x | 7.7x |
| 2020 | $40.66 | 17.2x | 8.6x |
| 2019 | $22.33 | 18.0x | 7.0x |
| 2018 | $16.48 | N/A | 8.3x |
| 2017 | $16.58 | N/A | N/A |
| 2016 | $16.58 | N/A | N/A |
P/E history is shown only for companies that report in US dollars.
GNG Valuation
| GNG view | Overvalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About GMAB
What is GMAB's forward P/E ratio?
Genmab AS has a forward P/E ratio of 22.2x.
Is GMAB stock overvalued?
GNG's valuation label for GMAB is Overvalued. Its P/E of 35.8x compares with a median of 19.3x across 5 similar companies.
What is GMAB's price to sales ratio?
Genmab AS has a price to sales ratio of 19.2x.
What is GMAB's PEG ratio?
Genmab AS has a PEG ratio of 4.6.
GMAB pages: Overview, Valuation, Competitors